Jain PharmaBiotech, Feb 2012, Pages: 639
of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical
TriMark Publications, July 2011, Pages: 214
and Comparison of Methods
4.2.3 Competitive Structure and Market Share Analysis
4.2.3.1 BreastCancer Molecular Diagnostic Testing Market Size
4.2.3.1.1 Global Market
4.2.3.1.2 U.S. Market
4.2.3.1.3 European
TriMark Publications, Sep 2011, Pages: 343
. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early
Frost & Sullivan, Feb 2008, Pages: 113
in the European biopsy devices market. The market was estimated at $213.8 million in 2007, with breast biopsy leading the overall market in terms of revenue contributions. According to WHO, globalcancer rates
TriMark Publications, Jan 2011, Pages: 156
Appendix 1: BreastCancer
Appendix 2: Ovarian Cancer
Appendix 3: Malignant Melanoma
INDEX OF TABLES
Table 2.1: Drug Development by Type of Cancer 10
Table 2.2: Organ-specific Medicines in Development
Business Insights, Aug 2004, Pages: 155
) to the company’s prescription product sales of SwFr 21.6b...”
This report will provide the answers to your questions, such as...
- What is the impact of declining R&D productivity on the future of cancer drug
Research Facts Ltd, April 2009, Pages: 107
.
The CRO’s profiled in this report have expertise in all types of cancer e.g. BreastCancer, NSCLC and SCLC, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Kidney Cancer, Hematologic
Netscribes (India) Pvt. Ltd., Aug 2011, Pages: 41
Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer
Global Industry Analysts, Inc., July 2009, Pages: 558
II-3
Rising Incidences of Cancer & Unmet Treatment Needs: A Prime
Driver II-4
Table 2: Global New Cases Registered
Bioseeker, Sep 2011, Pages: 1944
of every nine cancer indications described, and more so in BreastCancer, Colorectal Cancer and non-Hodgkin's Lymphoma. Here, Ewing's Sarcoma makes out its own class by having five drugs but only towards one
Markets and Markets, Nov 2010, Pages: 179
– 2015 ($Million)
29 Globalbreastcancer market, by geography 2008 – 2015 ($Million)
30 Global head and neck cancer market, by geography 2008 – 2015 ($Million)
31 Global cardiology market, by geography
Jain PharmaBiotech, Feb 2012, Pages: 607
capture microdissection technology and cancer proteomics
Cancer tissue proteomics
Use of proteomics in cancers of various organ systems
Proteomics of brain tumors
Proteomics of breastcancer
Proteomics
TriMark Publications, July 2011, Pages: 335
.2.5.7 BreastCancer
3.2.5.8 Bladder Cancer
3.2.5.9 Ovarian Cancer
3.2.5.10 Molecular Diagnostic Screening Test for Cancer
3.2.5.11 Cervical Cancer
3.2.6 Microbiology Testing Using Molecular Diagnostics
3
Global Industry Analysts, Inc., Feb 2010, Pages: 361
Hopkins Scientists Reveal Epigenetic Modifications Take
Place Over Lifetime II-33
Advances in Epigentic Regulation Focuses on BreastCancer
TriMark Publications, May 2011, Pages: 239
Market for Biomarkers, 2009-2014 69
Figure 3.16: Biomarker Patent Filings by Type of Cancer, 2010 71
Figure 3.17: Global Market for BreastCancer, 2009-2016 72
Figure 3.18: Global Market for Medical Displays and Post
GlobalData, Sep 2011, Pages: 40
for the treatment of breast, and other cancers and to alleviate the symptoms of menopause. The company’s product pipeline includes Menerba, Seala (formerly VG101), Bezielle, BN107, and BN108. Menerba, is a selective
Decision Resources, Inc., March 2009, Pages: 31
Behavior
Nexus Between Personalized Healthcare and Information Privacy
List of Tables
- Personalized Medicine Return on Investment: Two Studies on Newly Diagnosed BreastCancer
- Medco’s R&D Pipeline
GlobalData, Aug 2011, Pages: 44
immunotherapy technologies to treat glioblastoma and other multiple cancers such as pancreatic, colon and breastcancers due to presence of similar epitopes on these malignant cells. Its product candidates
